Морфологічні зміни в легенях за умов дії кверцетину на тлі хронічної експериментальної гіперглікемії by Теслик, Тетяна Петрівна et al.
 © Sumy State University, 2019 © Сумський державний університет, 2019 
 
 
Abstract        УДК 616.131:616.379-008.64-092.9-085  
T. P. Teslyk,  
V. Z. Sikora, 
Sumy State University, 2, 
Rymskogo-Korsakova st., 40007 
Sumy, Ukraine 
MORPHOLOGICAL CHANGES IN THE LUNGS IN 
THE CONTEXT OF QUERCETIN EFFECT AGAINST 
THE BACKGROUND OF CHRONIC EXPERIMENTAL 
HYPERGLYCEMIA. 
 
The widespread prevalence of diabetes, the early disability of the 
patients, and their high mortality have allowed WOH experts to determine 
the situation with diabetes as an epidemic of non-infectious disease, in 
which, in addition to carbohydrate disorders, there are deviations in all 
types of metabolism. The issue of etiotropic treatment of diabetes remains 
open today. The influence on the pathogenetic links of chronic 
hyperglycaemia often does not solve the problem of metabolic disorders 
and, as a result, does not prevent the occurrence of complications. In 
connection with this, there is a need to include treating with antioxidant 
and angioprotective properties in the treatment of patients with type I 
diabetes along with hypoglycaemic drugs. Macro- and microangiopathy, 
which lead to pneumosclerosis with impaired lung elasticity, serve as 
morphological evidence of affecting pulmonary structures by products of 
metabolism impaired as a result of chronic hyperglycemia.  In view of this, 
we conducted a study of the structures of pulmonary tissue, blood vessels, 
and lymphoid follicles in the context of chronic alloxan hyperglycemia 
against the background of quercetin use. The drug is widely used in 
medical practice due to its broad-spectrum action.. 
The research was conducted involving 72 white laboratory rats of both 
sexes, aged 1 to 7 months, weighing 170.1 ± 0.13 g. Experimental animals 
were divided into two subgroups: 1) with aloxane hyperglycemia (36 rats), 
which served as control and 2) of rats who at the same time used quercetin 
(36 rats). The above subgroups were divided into six subgroups depending 
on the duration of the study: the first one – with the term of hyperglycemia 
30 days, the second – 60 days, the third – 90 days, the fourth – 120 days, 
the fifth – with 150 days, the sixth – with the term hyperglycemia 180 days 
In accordance with a series of animals with experimental hyperglycemia 
with a duration of 30 to 180 days, the slaughter of rats of the 
corresponding age using the therapeutic agent was performed by thoracic 
intubation under the thoracic thiopental-sodium anesthesia. For 
experimental modeling of hyperglycemia, we used chemical compound 
alloxan.  
As a result of the experiment, it was found that quercetin, due to the 
properties of reducing the permeability of the vascular wall, contributed to 
the reduction of the stasis; anti-inflammatory and immunomodulatory 
effect – reduction of size of lymphoid follicles, proliferation of 
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macrophages in comparison with naive animals. The anti-sclerotic effect 
of quercetin has been shown to slow down the development of fibrosis in 
the walls of the pulmonary vessels of the muscular type. On the 
background of his admission, the process of development of 
microangiopathy in the capillaries of interalveolar membranes was 
inhibited. But given that the protective properties of quercetin were 
demonstrated at the end of the experiment, it can be argued that the effect 
of accumulation is influenced. The analysis of micromorphometric indices 
in animals treated with quercetin showed a decrease in the intensity of 
emphysematic reconstruction of pulmonary structures against chronic 
hyperglycemia. These findings provide the basis for the use of quercetin 
for the prevention and treatment of initial complications of hyperglycemia 
as a corrector. 
Keywords: aloxane hyperglycemia, rats, pulmonary arteries of the 
muscular type, quercetin, thickness of the alveolar barrier, thickness of the 
interstitium, thickness of the interalveolar septum, broncho-pulmonary 
lymph nodes.– 
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МОРФОЛОГІЧНІ ЗМІНИ В ЛЕГЕНЯХ ЗА УМОВ ДІЇ 
КВЕРЦЕТИНУ НА ТЛІ ХРОНІЧНОЇ 
ЕКСПЕРИМЕНТАЛЬНОЇ ГІПЕРГЛІКЕМІЇ 
  
Цукровий діабет – це група метаболічних захворювань, які харак-
теризуються хронічною гіперглікемією, що є результатом порушення 
секреції інсуліну, його властивостей або комбінацією обох факторів. 
Хронічна гіперглікемія при цукровому діабеті супроводжується ура-
женням, дисфункцією та недостатністю різних органів, особливо зо-
рового аналізатору, нирок, нервів, серця та кровоносних судин. 
Паралельно з вивченням впливу гіперглікемії на організм, ведеть-
ся пошук коректора, який міг би максимально нівелювати його. Ве-
лика увага приділяється препаратам, які володіють антиоксадантни-
ми та антидіабетогеннми властивостями. Незважаючи на це, дослі-
дження направлені на виявлення протективного ефекту лікувальних 
засобів на організм вцілому, без детального вивчення органів респі-
раторної системи. 
В статті описані зміни в легенях, легеневих артеріях м’язового 
типу, легеневих лімфоїдних фолікулах тварин, що перебували за 
умов хронічної гіперглікемії терміном 30 - 180 діб, та щурів, що од-
ночасно вживали Кверцетин на тлі експерименту.  
Зважаючи на характер змін у структурах легеневої тканини, та з 
метою корекції патогенетичних ланок розвитку алоксанової гіперглі-
кемії, був обраний лікувальний засіб Кверцетин у вигляді гранул. 
Препарат чинить вплив на стінку капілярів, клітинних мембран, в 
результаті чого зменшується проникність судин та виникає антиок-
сидантний ефект. Кверцетин, блокуючи ліпооксигеназний шлях ме-
таболізму арахідонової кислоти, зменшує розвиток запальних реак-
цій. Препарат володіє імуномодулюючою та антисклеротичною влас-
тивістю. Експериментально доведено, що Кверцетин стимулює виві-
льнення інсуліну. 
У тварин на тлі прийому препарату, у порівнянні з щурами, що не 
вживали Кверцетин, стаз у легеневих артеріях розвивався пізніше; 
імуномодулюючий його ефект сприяв менш активній гіпертрофії 
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лімфоїдних фолікулів та гіперплазії макрофагів. Антисклеротична дія 
Кверцетину виявилась у сповільненні розвитку фіброзу у стінках 
легеневих судин м’язового типу. Зважаючи на те, що свої протектив-
ні властивості препарат проявив у кінці експерименту, можна ствер-
джувати про вплив ефекту накопичення. 
Ключові слова: алоксанова гіперглікемія, щурі, легеневі артерії 
м’язового типу, Кверцетин, товщина альвеолярного бар’єру, тов-
щина інтерстицію, товщина міжальвеолярної перетинки, лімфоїдні 
фолікули.  
 
Автор, відповідальний за листування: tesluk.tanya@ukr.net
 
Introduction 
The widespread prevalence of diabetes mellitus, 
early disability of patients and high mortality have 
given WHO experts the reason to identify the 
diabetes situation as an epidemic of non-infectious 
disease, in which except for carbohydrate disorders 
there are problems with all types of metabolism [1].  
The issue of etiotropic therapy for diabetes 
mellitus remains topical. Influencing the 
pathogenetic mechanisms of chronic hyperglycemia 
development often does not solve the problem of 
metabolic disorders and, as a consequence, does not 
prevent complications. In this regard, there is a 
need to include therapies with antioxidant and 
angioprotective properties in the treatment regime 
of patients with type 1 diabetes, along with the 
sugar-lowering drugs.  
Macro- and microangiopathy, which lead to 
pneumosclerosis with impaired lung elasticity, 
serve as morphological evidence of affecting 
pulmonary structures by products of metabolism 
impaired as a result of chronic hyperglycemia. Such 
changes of pulmonary tissue are described in the 
few works of domestic and foreign scientists 
Stepanian I. E., Sokolov Ye. I. and Rekha 
Jagadapillai [2, 3, 4]. In view of this, we conducted 
a study of the structures of pulmonary tissue, blood 
vessels, and lymphoid follicles in the context of 
chronic alloxan hyperglycemia against the 
background of quercetin use. The drug is widely 
used in medical practice due to its broad-spectrum 
action. Due to the capillary-stabilizing properties 
associated with the antioxidative and membrane-
stabilizing effect, the drug reduces capillary 
permeability. Quercetin has an anti-inflammatory 
effect due to the blockade of lipoxygenase pathway 
of arachidonic acid metabolism and reduced 
synthesis of leukotrienes, serotonin and other 
mediators of inflammation. The drug has 
immunomodulatory activity. The antisclerotic 
properties were experimentally determined. 
Quercetin is capable of stimulating insulin release 
and inhibiting thromboxane synthesis [5, 6, 7]. 
The aim of the study was to define the influence 
of quercetin on changes in the morphology of 
muscular type pulmonary vessels, structural 
components of the lungs at micro- and 
ultrastructural levels, pulmonary lymphoid follicles 
in the context of chronic alloxan hyperglycemia. 
Materials and methods. The studies were 
performed involving 72 white laboratory rodents of 
both sexes, 1 to 7 months old, of 170.1±0.13 g. The 
experimental animals were divided into two groups: 
1) rats with alloxan hyperglycemia (36 rats), which 
served as the controls and 2) rats that were given 
quercetin apart from that (36 rats). The above 
subgroups were divided into six more subgroups, 
depending on the study period: subgroup I – with 
30-days hyperglycemia, subgroup II – with 60-days 
hyperglycemia, subgroup III – with 90-days 
hyperglycemia, subgroup IV – with 120-days 
hyperglycemia, subgroup V – with 150-days 
hyperglycemia, subgroup VI – with 180-days 
hyperglycemia. In accordance with the series of 
animals with experimental 30 to 180 days 
hyperglycemia, the rats of the appropriate age that 
were given the drug, were sacrificed by cutting the 
chest under intra-abdominal thiopental sodium 
anesthesia. 
The animals were kept in the vivarium of the 
Department of Morphology of Medical Institute, 
Sumy State University. Before the study, each 
group of rats had a two-week quarantine. Animals 
were kept according to standard guidelines, 
requirements and regulations for laboratory animal 
care (provisions of the "European Convention for 
the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes" 
(Strasbourg, 1985); "Regulations for the Procedures 
Involving Experimental Animals", Annex 4, 
approved by the Order of the Ministry of Health 
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No. 755 dated August 12, 1997; "On Measures to 
Further Improvement of the Organizational Forms 
of Procedures Involving Experimental Animals"; 
Declaration of Helsinki of the General Assembly of 
the World Medical Association (2000); "General 
Ethical Principles for Animal Experiments" 
approved by the First National Congress on 
Bioethics (Kyiv, 2001); regulations approved by the 
Bioethics Committee of Medical Institute of Sumy 
State University (Protocol No. 4 dated December 
22, 2009). There were no violations of moral and 
ethical standards during the study. 
For experimental modeling of hyperglycemia, 
we used chemical compound alloxan. After 24-hour 
fasting on the background of normal blood tests, the 
animals were subcutaneously injected with a 
solution of alloxan monohydrate 20 mg per 100 g 
of rat body weight in 0.1 M citrate buffer (pH 4.0).  
 The following methods were used: histologic 
(using van Gieson's stain method with hematoxylin 
and eosin), ultramicroscopic with dynamic 
morphometry using the universal certified program 
"SEO Scan Lab 2.0" and "SEO Image Lab 2.0".  
We measured the wall thickness of the muscular 
type pulmonary arteries, perimeter of the lymphoid 
follicles, width of the alveoli, depth of the alveoli, 
width of the alveolar duct entrance, width of the 
conductive bronchioles, thickness of the 
interalveolar septa, thickness of interstitial tissue, 
thickness of blood-air barrier. Blood glucose levels 
were also determined by means of glucose oxidase 
method using Filisit reagent kits («Філісіт», 
Ukraine) and the level of glycated hemoglobin 
(HbA1c) was measured using ВioSystems reagent 
kits (Spain) before each sacrifice of animals.  
All figures obtained were statistically processed 
using Acer personal computer and a licensed 
spreadsheet editor Microsoft Office Excel 2013. 
The arithmetic mean (M), the mean error of the 
mean (m) were calculated. The significance of the 
difference (p) was determined using Student's t test 
(t), with the error being less than 5% (p <0.05).  
Study results and discussion. During the first 
experimental month, the animals had classic 
symptoms of hyperglycemia: polyuria, polyphagia, 
polydipsia. Blood glucose levels ranged 13.1 to 
19.3 mmol/L, glycated hemoglobin increased 
starting from the 90-th day of the experiment (8.2 ± 
0.4%), indicating chronic hyperglycemia in 
animals.  
No visible changes were detected in the lung 
tissue during microscopic examination from the 30-
th to 150-th day, but on the 180-th day of chronic 
hyperglycemia accompanied by the administration 
of quercetin a small intravascular accumulation of 
blood elements in some vessels was found. There 
was a slight increase in mature collagen fibers in 
the walls of the muscular type arteries (t.media et 
t.externa), as well as interalveolar septa. Some 
specimens showed signs of focal dystelectasis and 
minor hypertrophy of lymphoid follicles. 
The proliferation of type II alveolocytes was 
observed from the fourth month of the experiment, 
but to a lesser extent than in the rats with chronic 
hyperglycemia that were not given quercetin.The 
effect of quercetin on the thickness of the blood-air 
barrier (BAB) was detected as early as on the 60-th 
day of its administration to animals. The BAB 
value (418.4±1.1 nm) in the drug-receiving animals 
was 0.41% (p <0.05) less than in the animals that 
were not given it (BAB was 420.1±0.4 nm). These 
phenomena were observed against the background 
of reduced vacuolization in pneumocytes and lesser 
sclerosis of the pulmonary stroma than in animals 
with hyperglycemia (Fig. 1). 
The antioxidative properties of quercetin have 
been shown to slow the development of sclerotic 
changes in pulmonary interstitium against the 
background of chronic hyperglycemia since the 
60th day of the experiment, the thickness of 
interstitium (TI) (81.3±0.31 nm) was less by 0.74% 
(p <0.05) than that in animals that were not given 
quercetin (TI was 81.9±1.14 nm). The processes of 
macrophage proliferation and destruction of type II 
alveolocytes were lesser than those in the control 
group (Fig. 2). 
Quercetin-induced initial changes at microlevel 
in pulmonary tissue structures began on the 150-th 
day of alloxan hyperglycemia. Width of the alveoli 
(81.9±0.18 µm) (WA) was significantly lesser than 
that in the quercetin-naive animal group (83.1±0.43 
µm) by 1.5% (p <0.05) and on the 180-th day, when 
restrictive changes prevailed, this value increased 
by 1.9% (p <0.05) as compared to the animals with 
hyperglycemia. Depth of the alveoli (DA) increased 
from 150-th day by 0.2% (p <0.05) and increased 
by 18.8% (p <0.05) by the 180-th day as compared 
with quercetin-naive animals. Width of the alveolar 
duct entrance (WAE) varied from 150-th day of 
experience: after five months of the experiment 
WAE in quercetin-treated animals was 1.4% less (p 
<0.05) as compared with rats with hyperglycemia; 
after six months it was 11.5% less (p <0.05). 
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Figure 1 – Effect of quercetin on ultramicroscopic lung structures of rodents with chronic 
hyperglycemia. AH – alloxan hyperglycemia, BAB – thickness of blood-air barrier, ET – endothelial cell 
thickness, TA – thickness of alveolocyte, TI – thickness of interstitium  
 
 
 
Figure 2 – Cell structure of lung tissue in young rats with experimental hyperglycemia lasting 60 days 
(2) and against the background of quercetin administration (1). Toluidine blue stain ×1000. 1.1 – a single 
macrophage in the lumen of the alveoli; 1.2 – macrophage accumulation in the lumen of the alveoli 
 
Width of the conductive bronchioles (WCB) in 
the background of quercetin administration 
increased less actively as compared with the 
quercetin-naive group by the 150-th day of 
experiment, their size was 0.14% smaller (p <0.05) 
and up to the 180-th day it increased by 1.3% 
(p <0.05) (quercetin-naive rats had this index 
increased by 21.8% (p <0.05)). Thickness of the 
interalveolar septa (TIS) was less from the 150-th 
day of the experiment against the background of 
quercetin administration (in five months by 4.9% (p 
<0.05), in six months by 61.5% (p <0.05)). Depth 
of the alveoli (DA) after six months of the 
experiment was 8.3% more in quercetin-receiving 
animals (p <0.05) than that in the naive group 
(Fig. 3). 
The walls of the muscular type pulmonary 
arteries were not significantly thickened since the 
fifth month of the experiment in the background of 
quercetin administration. Compared with the 120-th 
day of the experiment, the thickness of the vessel 
wall (TVW) decreased by 0.72% (p <0.05 (from 
115.7±0.36 μm to 115.5±0.14 μm) (in quercetin-
naive group TVW increased by 1.34% (p <0.05) 
from 115.7±0.36 μm to 116.2±1.4 μm). On the 180-
th day of the experiment, TVW (115.5 ± 0.08 μm) 
was 2.59% (p <0.05) lower than that in the group of 
quercetin-naive animals (TVW was 118.5 ± 
0.44 μm). The reduction of the TVW by 120-th day 
was due to a significant 1.1% decrease in the 
thickness of the vessel outer coat (p <0.05).  
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Figure 3 – Effect of quercetin on texture of lungs, muscular type pulmonary arteries, lymphoid follicles 
in rodents with chronic hyperglycemia. AH – alloxan hyperglycemia, LFP – lymphoid follicles perimeter, 
TVW – thickness of vessel wall, WA – width of alveoli, DA – depth of alveoli, WAE – width of the alveolar 
duct entrance, WCB – width of the conductive bronchioles, TIS – thickness of the interalveolar septa 
Reaction of peripheral immune system organs 
started on the 60-th day on the background of 
quercetin administration. Size of lymphoid follicles 
on the 90th day of the experiment was 1.2 (p <0.05) 
times smaller than that in the quercetin-naive group. 
On the 120-th, 150-th, and 180-th days of chronic 
hyperglycemia, lymphoid follicles perimeters were 
1.14, 1.73, and 1.5 (p <0.05) times lesser, 
respectively, than in quercetin-naive groups, 
confirming data on quercetin high protective 
effectiveness (Table 1). 
 
Conclusions  
The antisclerotic effect of quercetin has been 
found to slow the hyperplasia of mature collagen 
fibers in the outer coat and myocytes in the middle 
membrane of muscular type pulmonary vessels. 
However, due to the fact that quercetin showed its 
protective properties at the end of the experiment, 
accumulation effect can be assumed. Analysis of 
micromorphometric parameters in quercetin-
receiving animals from 30 to 180 days of the exper-
iment showed an increase in WA by 15.4% (p 
<0.05), in quercetin-naive rats – by 12.7% (p 
<0.05); WAE – by 55.7% (p <0.05), in quercetin-
naive rats – 73.7% (p <0.05); WCB increased by 
43.9% (p <0.05) in experimental rats, in the control 
rats – by 55.6% (p <0.05), indicating lower intensi-
ty of emphysematous remodeling of the pulmonary 
structures, which occurred along with restrictive 
changes. Fibrosis development in the interalveolar 
septa and blood-air barrier structures was less ac-
tive in experimental rats receiving quercetin (BAB 
increased by 6.7% (p <0.05) in the background of 
quercetin use from the 30-th to 180-th days of the 
experiment), whereas in the animals with hypergly-
cemia it was 9.3% (p <0.05). The size of lymphoid 
follicles in experimental rats increased 5.4 times (p 
<0.05) by the end of the experiment, and 8.2 times 
(p <0.05) in the control rats. These findings provide 
the basis for quercetin being used as a corrector for 
prevention and treatment of initial hyperglycemia 
complications. 
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Table 1 - Results of the study of pulmonary tissue in young rats with alloxan hyperglycemia with and without quercetin (M ± m), n = 6  
Value 30 days 60 days 90 days 120 days 150 days 180 days 
 Que No que Que No que Que No que Que No que Que No que Que No que 
TVW, µm 34.2 34.2 41.8 41.8 115.6 115.6 115.7 115.7 115.5* 116.2 115.5* 118.5 
 ±0.58 ±0.04 ±0.63 ±0.02 ±0.49 ±0.1 ±0.14 ±0.36 ±0.14 ±1.4 ±0.08 ±0.44 
LFP, µm 449.3 449.3 1049.0* 1049.6 1156.2* 1330.0 1254.7* 1430.1 1305.3* 2260.1 2447.3* 3690.1 
 ±0.8 ±0.7 ±0.82 ±0.6 ±1.3 ±0.8 ±0.51 ±0.2 ±0.4 ±0.5 ±0.3 ±0.5 
Glucose, mmol/L 19.3 19.3 13.81 13.8 13.3 13.3 13.5 13.5 13.69 13.7 8.09 13.1 
 ±0.21 ±0.22 ±0.8 ±0.4 ±1.3 ±0.1 ±0.11 ±0.17 ±0.15 ±0.9 ±0.11 ±0.2 
HbА1С, % 7.11 7.1 7.16 7.18 8.2 8.2 8.6 8.59 9.31 9.3 9.4 9.39 
 ±0.4 ±0.15 ±0.9 ±0.4 ±0.4 ±0.26 ±0.4 ±0.8 ±0.24 ±0.41 ±0.58 ±0.28 
BAB, nm 414.8 414.8 418.4* 420.1 436.7* 452.8 440.54* 453.31 441.2* 453.4 442.6* 453.4 
  ±0.8 ±0.13 ±1.1 ±0.4 ±0.2 ±0.53 ±0.27 ±0.04 ±0.92 ±0.08 ±0.2 ±0.63 
TI, nm 80.2 80.2 81.3* 81.9 97.6* 105.1 97.63* 105.3 98.1* 105.3 98.4* 105.3 
 ±0.8 ±0.13 ±0.31 ±1.14 ±0.42 ±0.1 ±0.18 ±0.4 ±0.12 ±0.27 ±0.3 ±0.15 
DA, µm 52.2 52.18 53.6 53.6 55.8 55.8 52.33* 52.3 49.69* 46.9 53.2* 44.8 
 ±0.67 ±0.37 ±0.01 ±0.4 ±0.05 ±0.12 ±0.71 ±0.08 ±0.14 ±0.03 ±0.3 ±0.06 
WAE, µm 31.14 31.14 31.14 31.14 31.2 31.2 43.18* 43.2 48.65* 49.4 48, *5 54.1 
 ±0.91 ±0.12 ±0.5 ±0.01 ±0.03 ±0.4 ±0.5 ±0.12 ±0.2 ±0.33 ±0.2 ±0.6 
WCB, µm 61.05 61.05 62.003 62.003 63.5 63.5 70.3 70.3 77.9* 78.02 87.9* 95.02 
 ±0.5 ±0.71 ±0.9 ±0.1 ±0.4 ±0.11 ±0.2 ±0.9 ±0.82 ±0.51 ±0.8 ±0.61 
TIS, µm 6.3 6.3 6.9 6.9 7.0 7.03 7.5 8.0 8.6* 9.02 9.3* 15.02 
 ±0.4 ±0.04 ±0.05 ±1.3 ±0.2 ±0.5 ±0.41 ±0.17 ±0.1 ±0.4 ±0.1 ±0.04 
WA, µm 68.31 68.3 72.1 72.1 78.3 78.3 89.4 89.4 81.9* 83.1 78.5* 77.0 
 ±0.1 ±0.5 ±0.09 ±0.5 ±0.21 ±0.19 ±0.17 ±0.31 ±0.18 ±0.43 ±0.6 ±0.21 
Note: * – deviation was significant for the quercetin-naive group (p <0.05)
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